The estimated Net Worth of Blair Curtis Jackson is at least $4.3 Milión dollars as of 23 February 2024. Mr Jackson owns over 8,737 units of Alkermes plc stock worth over $4,295,891 and over the last 4 years he sold ALKS stock worth over $0.
Mr has made over 11 trades of the Alkermes plc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 8,737 units of ALKS stock worth $232,142 on 23 February 2024.
The largest trade he's ever made was exercising 49,999 units of Alkermes plc stock on 20 April 2022 worth over $827,483. On average, Mr trades about 12,815 units every 79 days since 2021. As of 23 February 2024 he still owns at least 161,682 units of Alkermes plc stock.
You can see the complete history of Mr Jackson stock trades at the bottom of the page.
Blair C. Jackson is the Exec. VP & COO at Alkermes plc.
Mr Jackson is 48, he's been the Exec. VP & COO of Alkermes plc since . There are 21 older and no younger executives at Alkermes plc. The oldest executive at Alkermes plc is Dr. Floyd E. Bloom M.D., 84, who is the Founder.
Blair's mailing address filed with the SEC is 850;852, Winter Street, Lincoln, Middlesex County, Massachusetts, 02451, United States.
Over the last 13 years, insiders at Alkermes plc have traded over $407,046,771 worth of Alkermes plc stock and bought 86,119 units worth $2,034,840 . The most active insiders traders include Corp Plc Elan Science Three..., Richard F Pops a James M Frates. On average, Alkermes plc executives and independent directors trade stock every 5 days with the average trade being worth of $1,083,232. The most recent stock trade was executed by David Joseph Gaffin on 3 August 2024, trading 2,014 units of ALKS stock currently worth $53,512.
alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (cns) diseases. the company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. headquartered in dublin, ireland, alkermes plc has an r&d center in waltham, massachusetts; a research and manufacturing facility in athlone, ireland; and a manufacturing facility in wilmington, ohio. for more information, please visit alkermes’ website at www.alkermes.com.
Alkermes plc executives and other stock owners filed with the SEC include: